An observational study to evaluate the safety and efficacy of lenvatinib plus pembrolizumab combination therapy for advanced or recurrent uterine cancer after use of platinum-based drugs(GOGO-EM4)

Not Applicable

• Conditions: Advanced or recurrent uterine cancer

• Registration Number: JPRN-UMIN000049997
• Lead Sponsor: Gynecologic Oncology Group of Osaka(GOGO)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-01-10
• Last Update Posted: 17 October 2023
• Study Completion: 2030-03-31

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with recurrent endometrial cancer who have not received any chemotherapy, including platinum-based antineoplastic agents 2. Cases with obvious infection 3. Cases with active multiple cancers 4. Patients with persistent adverse events (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0 Grade 2 or higher) from prior chemotherapy(Excluding epilation and peripheral neuropathy) 5. Cases with hematologic complications 6. Cases with a history of bone marrow transplantation 7. Cases with uncontrolled brain metastases 8. Patients with serious complications (cardiac disease, uncontrolled diabetes, malignant hypertension, bleeding tendency, etc.) 9. Pregnant or lactating patients and patients of childbearing potential (will) (except for patients using appropriate contraceptive methods) 10. Any other cases other than those listed above that the principal investigator deems inappropriate for enrollment of the case in the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified